Do analysts rate ABP or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ABP or CURX?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A

Is ABP or CURX more profitable?

Abpro's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts prefer ABP or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ABP or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ABP or LIAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, ABP or LIAN?

Abpro is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is ABP or LIAN more profitable?

Abpro's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% LianBio N/A -33.17% -30.19%

Do analysts prefer ABP or RVPH?

Reviva Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 15,773.02%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Abpro. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, ABP or RVPH?

Abpro is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is ABP or RVPH more profitable?

Abpro's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Reviva Pharmaceuticals N/A -391.58% -119.08%

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 08/7/2026

Compare

ABP vs. CURX, INM, SNOA, LIAN, and RVPH

Should you buy Abpro stock or one of its competitors? MarketBeat compares Abpro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abpro include Curanex Pharmaceuticals (CURX), InMed Pharmaceuticals (INM), Sonoma Pharmaceuticals (SNOA), LianBio (LIAN), and Reviva Pharmaceuticals (RVPH).

How does Abpro compare to Curanex Pharmaceuticals?

Abpro (NASDAQ:ABP) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

23.3% of Abpro shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Abpro's average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Curanex Pharmaceuticals	Neutral

Abpro's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Summary

Abpro and Curanex Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Abpro compare to InMed Pharmaceuticals?

Abpro (NASDAQ:ABP) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Abpro has higher earnings, but lower revenue than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A

Abpro has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Abpro's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

23.3% of Abpro shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Abpro's average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
InMed Pharmaceuticals	Neutral

Summary

Abpro beats InMed Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Abpro compare to Sonoma Pharmaceuticals?

Abpro (NASDAQ:ABP) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

23.3% of Abpro shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 0 mentions for Abpro. Sonoma Pharmaceuticals' average media sentiment score of 1.33 beat Abpro's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Sonoma Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Abpro has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Abpro's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Sonoma Pharmaceuticals	-10.33%	-26.32%	-6.55%

Sonoma Pharmaceuticals has higher revenue and earnings than Abpro. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Sonoma Pharmaceuticals	$19.53M	0.32	-$3.17M	-$1.22	N/A

Summary

Abpro and Sonoma Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Abpro compare to LianBio?

Abpro (NASDAQ:ABP) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Abpro's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
LianBio	N/A	-33.17%	-30.19%

23.3% of Abpro shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Abpro's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
LianBio	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Abpro is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Summary

Abpro and LianBio tied by winning 4 of the 8 factors compared between the two stocks.

How does Abpro compare to Reviva Pharmaceuticals?

Abpro (NASDAQ:ABP) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Abpro's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Reviva Pharmaceuticals and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Reviva Pharmaceuticals	Neutral

Abpro is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

23.3% of Abpro shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Reviva Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 15,773.02%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Reviva Pharmaceuticals beats Abpro on 8 of the 11 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.12	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	-0.06	17.97	11.40	6.45
Net Income	-$7.23M	-$13.25M	$3.45B	$347.50M
7 Day Performance	N/A	5.58%	3.66%	3.77%
1 Month Performance	N/A	-1.60%	-0.49%	-0.40%
1 Year Performance	-92.93%	61.32%	77.51%	23.55%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
CURX Curanex Pharmaceuticals	0.8504 of 5 stars	$0.19 -2.2%	N/A	N/A	$5.62M	N/A	N/A	N/A	Positive News Gap Up
INM InMed Pharmaceuticals	1.2099 of 5 stars	$1.67 flat	N/A	-34.4%	$5.53M	$4.94M	N/A	10
SNOA Sonoma Pharmaceuticals	1.1311 of 5 stars	$1.10 -3.5%	N/A	-52.9%	$5.46M	$19.53M	N/A	180	Positive News Earnings Report Analyst Upgrade
LIAN LianBio	N/A	$0.05 flat	N/A	-8.3%	$5.40M	N/A	N/A	110	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. CURX, INM, SNOA, LIAN, and RVPH

How does Abpro compare to Curanex Pharmaceuticals?

Summary

How does Abpro compare to InMed Pharmaceuticals?

Summary

How does Abpro compare to Sonoma Pharmaceuticals?

Summary

How does Abpro compare to LianBio?

Summary

How does Abpro compare to Reviva Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. CURX, INM, SNOA, LIAN, and RVPH

How does Abpro compare to Curanex Pharmaceuticals?

Which has higher valuation & earnings, ABP or CURX?

Do insiders and institutionals have more ownership in ABP or CURX?

Do analysts rate ABP or CURX?

Does the media favor ABP or CURX?

Is ABP or CURX more profitable?

Summary

How does Abpro compare to InMed Pharmaceuticals?

Do analysts prefer ABP or INM?

Which has higher earnings and valuation, ABP or INM?

Is ABP or INM more profitable?

Do institutionals and insiders believe in ABP or INM?

Does the media prefer ABP or INM?

Summary

How does Abpro compare to Sonoma Pharmaceuticals?

Do insiders & institutionals have more ownership in ABP or SNOA?

Does the media favor ABP or SNOA?

Do analysts recommend ABP or SNOA?

Is ABP or SNOA more profitable?

Which has higher earnings & valuation, ABP or SNOA?

Summary

How does Abpro compare to LianBio?

Is ABP or LIAN more profitable?

Do institutionals & insiders believe in ABP or LIAN?

Does the media favor ABP or LIAN?

Do analysts recommend ABP or LIAN?

Which has better valuation and earnings, ABP or LIAN?

Summary

How does Abpro compare to Reviva Pharmaceuticals?

Is ABP or RVPH more profitable?

Does the media favor ABP or RVPH?

Which has stronger earnings & valuation, ABP or RVPH?

Do insiders and institutionals hold more shares of ABP or RVPH?

Do analysts prefer ABP or RVPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools